Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.0%

Neg 0% Neu 91% Pos 0%

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $170 price target.

Comments

No comments yet. Be the first!